



Desmopressin as a valuable treatment option in a large proportion of patients with moderate hemophilia A

Hemophilia A

No treatment



DDAVP (Desmopressin)



169

Patients with moderate (FVIII:C measurements ≤ 5 IU/dL) Hemophilia A

99

59% Responsive to DDAVP (peak FVIII:C > 20 IU/dL)

25

15% Excellent response (peak FVIII:C ≥ 50 IU/dL)

43

25% Complete response (peak FVIII:C = 30-49 IU/dL)

31

18% Partial response (peak FVIII:C = 20-29 IU/dL)

Significant predictors of peak FVIII level →

- Intravenous administration
- Age
- pre-DDAVP FVIII:C activity*
- pre-DDAVP VWF antigen
- peak VWF activity
- DDAVP induced FVIII:C rise in VWF antigen*

*Predictors with the strongest effect